This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- 2-BBB Medicines BV
- Amicus Therapeutics, Inc.
- AngioChem Inc.
- Fate Therapeutics, Inc.
- Minoryx Therapeutics s.l.
- Nimbus Therapeutics, LLC
- Nuo Therapeutics, Inc.
- Orphazyme ApS
- Oxyrane Belgium NV
- Promosome, LLC
- REGiMMUNE Corporation
- Sangamo BioSciences, Inc.
- Ultragenyx Pharmaceutical Inc.
- Chaperone-ERT Combinations
- Recombinant Enzyme for Farber Disease and Cystic Fibrosis
- Recombinant Enzyme for LSD-2 Disease
- Recombinant Enzyme for LSD-3 Disease
- Recombinant Enzyme for LSD-4 Disease
- Recombinant Enzyme for LSD-5 Disease
- Recombinant Enzyme for Lysosomal Storage Diseases and Metabolic Disorders
- Recombinant Enzyme for Lysosomal Storage Disorder
- Recombinant Enzyme to Target LRP1 for Lysosomal Storage Disorder
- Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease
- Small Molecules for GM1-gangliosidosis and Morquio B
- Small Molecules for Lysosomal Storage Disorders
- Stem Cell Therapy for Lysosomal Storage Disorder
Please find more about Lysosomal Storage Disorder - Pipeline Review, H2 2015 at reports.zursh.com
Click on below items to see free updates about the topic covered.
Click on below items to see free resources and reports about the topic covered.